KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cme Group (CME) Asset Writedowns and Impairment: 2009-2021

Historic Asset Writedowns and Impairment for Cme Group (CME) over the last 2 years, with Dec 2021 value amounting to -$600,000.

  • Cme Group's Asset Writedowns and Impairment rose 45.45% to -$600,000 in Q4 2021 from the same period last year, while for Dec 2021 it was -$1.1 million, marking a year-over-year decrease of 104.18%. This contributed to the annual value of $26.3 million for FY2020, which is 56.96% down from last year.
  • Cme Group's Asset Writedowns and Impairment amounted to -$600,000 in Q4 2021, which was down 700.00% from $100,000 recorded in Q3 2021.
  • Cme Group's Asset Writedowns and Impairment's 5-year high stood at $39.5 million during Q3 2019, with a 5-year trough of -$9.5 million in Q4 2018.
  • Over the past 3 years, Cme Group's median Asset Writedowns and Impairment value was $500,000 (recorded in 2021), while the average stood at $9.7 million.
  • As far as peak fluctuations go, Cme Group's Asset Writedowns and Impairment spiked by 315.79% in 2019, and later tumbled by 101.27% in 2020.
  • Over the past 4 years, Cme Group's Asset Writedowns and Impairment (Quarterly) stood at -$9.5 million in 2018, then surged by 315.79% to $39.5 million in 2019, then slumped by 101.27% to -$1.1 million in 2020, then soared by 45.45% to -$600,000 in 2021.
  • Its Asset Writedowns and Impairment was -$600,000 in Q4 2021, compared to $100,000 in Q3 2021 and $500,000 in Q1 2021.